Adaptimmune Announces Changes to Board and Executive Leadership Team

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes to the Company's Board of Directors ("Board") and its Executive Leadership team, which are effective from November 14, 2025.

Christopher (Chris) Hill, currently Chief Financial Officer ("CFO") of the Company, has been appointed as Chief Executive Officer ("CEO") and a Director of the Company, succeeding Adrian Rawcliffe who has left in connection with the Company's restructuring. Mr. Hill is continuing to serve as CFO. William (Bill) Bertrand, formerly Chief Operating Officer, has also left the Company in connection with the restructuring.

Lawrence Alleva, a current Board member, has been appointed as Chairman of the Company succeeding David Mott who has served as a director since 2014 and as Chairman since 2017. Garry Menzel will also continue to serve on the Board. In addition to Mr. Mott, the following Board members have resigned: Andrew Allen, Ali Behbahani, John Furey, Priti Hegde and Kristen Hege.

Following the changes, the Board comprises Lawrence Alleva (Chairman), Garry Menzel and Chris Hill (also CEO and CFO).

The changes follow on from the voluntary delisting of the Company's American Depositary Shares ("ADSs") from Nasdaq on October 28, 2025. The Company's ADSs are quoted on the OTC Pink Limited Market under the symbol ADAPY.

Chris Hill, Adaptimmune's new Chief Executive Officer: "I am pleased to have been appointed to succeed Adrian who has served with Adaptimmune since 2015 as CFO and then CEO. I want to acknowledge the work of Adrian, Bill and my fellow Board members and thank them for their dedicated service over many years. The transaction with USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC (collectively, "US WorldMeds") meant that TECELRA could continue to be made available to patients, and since closing on July 31, 2025, work has been ongoing to ensure a smooth transition of activities associated with TECELRA, lete-cel and uza-cel. We will continue to support US WorldMeds as we work together with a goal to achieve approval for lete-cel in the hope that it will benefit patients in the future. In parallel, we are maintaining a focus on efforts to maximize value from our remaining assets, including programs targeting PRAME and CD70. The delisting from Nasdaq and deregistration should reduce our costs as a public company and further support our goal to maximize value going forward."